4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024672
CHIEF SCIENTIFIC OFFICER sold 527 shares at $27.54 ($14,512)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-10-01 | Sale 10b5-1 | −527 | $27.54 | $14,512 | 1,077,409 | I |
| Open-market sales · 527 sh · avg $27.54 · $14,512 | |||||||
Loading xslF345X05/form4-10032024_101013.xml…